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THE PEPTIDE/MHC CLASS I DISPLAY
Immune surveillance by CD8 + T cells is one of the key mechanisms for detecting and eliminating abnormal cells, including those infected with viruses or bacteria and tumor cells. CD8
+ T cells probe the repertoire of peptide/MHC class I (p/MHC I) complexes on the target cell surface for novel peptides that indicate expression of foreign or abnormal gene products. Because cells cannot distinguish their normal proteins from nonself or mutant proteins, they constitutively display peptides derived from all proteins. For effective immune surveillance it is essential that the major histocompatibility complex (MHC) class I (MHC I) molecules display as large a peptide repertoire as possible to include those originating from the novel genes. Analogous to gene-chips, which contain thousands of nucleotide sequences to allow simultaneous detection of a large number of, if not all, transcripts in a 0732-0582/02/0407-0463$14.00 463 cell, the peptides displayed by MHC molecules represent the entire ensemble of polypeptides expressed within a cell. The MHC molecules and the sets of peptides they display can therefore be considered nature's gene-chips that are probed by the CD8 + T cell repertoire. The essence of the MHC I antigen processing pathway is to load MHC I molecules with thousands of different peptides for display on the cell surface. This goal is accomplished by merging two distinct pathways: one for generating peptide receptive MHC I molecules in the endoplasmic reticulum (ER) and another for generating the pool of antigenic peptides in the cytoplasm. The two pathways merge when the cytoplasmic peptides are translocated into the ER by the transporter associated with antigen processing (TAP) and are made available to peptidereceptive MHC I molecules.
The pathway that generates the peptide-receptive MHC I involves several steps and key components. MHC I molecules are associated with TAP, and tapasin acts as a bridge between the two molecules. Also present in the TAP/tapasin/MHC complex are the chaperones calreticulin and calnexin, as well as the thiol oxidoreductase ERp57. This configuration places the peptide receptive MHC I molecules in the immediate vicinity of transported peptides and also retains empty MHC I molecules until they are loaded with appropriate peptides. Tapasin may also play a role in editing and/or loading the peptides. After MHC I molecules are loaded with the peptides, they are released from this complex and exit through check-points in the ER and make their way out to the cell surface. The loading complex, and the roles of the individual components in this process, have been the subject of several excellent reviews and are not considered here (1) (2) (3) (4) .
We have chosen to focus on the less well understood aspects of the pathway that generates antigenic peptides. The peptides are enormously diverse and yet precisely tailored to fit the highly polymorphic MHC I molecules present in the cell. Furthermore, the topological separation between the cytoplasm, the major site of proteolysis, and the ER, the site of MHC loading, poses a daunting challenge to the antigen processing machinery.
We begin with a brief description of the strengths and limitations of the methods most commonly used to dissect the antigen processing pathway. Next, we start at the beginning of the pathway to address key unanswered questions about the source of antigenic peptides ( Figure 1 ). Are these precursors proteins undergoing normal turnover, or are they newly synthesized gene products? We limit ourselves to endogenously synthesized precursors, leaving the question of crosspriming, in which MHC I molecules are loaded with peptides derived from exogneous antigens, to other excellent reviews (5) (6) (7) (8) . Third, we summarize our understanding of the endpoint of the pathway: the peptide/MHC complexes on the cell surface. Fourth, we examine the intermediate steps in the pathway, following the precursors as they are transformed from polypeptide chains into the precise peptides that are presented by the MHC I molecules. We focus on the proteolytic events required to generate the peptides. Where and how are the precursors degraded to generate the antigenic peptides? Is the precisely cleaved peptide 
METHODS FOR STUDYING THE MHC I ANTIGEN PROCESSING PATHWAY
Processing of polypeptides in the MHC I pathway results in surface expression of the p/MHC I complex, whose raison d'être is to serve as a potential ligand for CD8 + T cells. T cell assays have therefore remained the most convenient method to detect the existence of a specific p/MHC complex in intact antigen presenting cells (APC). Conventional assays measure the activation of cytotoxic CD8 + T cells (CTL) by specific lysis of APC or by cytokine secretion. The presence of the p/MHC can also be assayed using T cell hybridomas that secrete IL-2 (9) or accumulate β-galactosidase (lacZ) (10, 11) .
These assays are often used to compare p/MHC levels on various APC. However, such comparisons can be difficult because even low copy numbers can often maximally activate T cells. Many CD8 + T cells can detect peptides at low picomolar concentrations; nanomolar concentrations are generally more than saturating. In this case increasing p/MHC copy number will not increase the activation readout. Two apparently equivalent APC may in fact have very different p/MHC levels.
A technically demanding but more informative method for measuring processed peptides is to fractionate cell extracts by high performance liquid chromatography (HPLC) and to detect the naturally processed peptides in an exogenous assay using appropriate APC and T cells (12, 13) . The high resolution of HPLC permits the identification of extracted peptides as well as their relative amounts by comparison with synthetic peptide standards.
MHC-bound peptides have also been detected and identified by massspectrometry (14, 15) . This technique has been particularly successful in revealing posttranslational modifications in the antigenic peptides (16) (17) (18) . Another method to detect the p/MHC I complex in the APC using a monoclonal antibody has recently emerged. This antibody was generated in the Germain laboratory, and it recognizes the ovalbumin (OVA)-derived SIINFEKL (SL8) peptide bound to the mouse K b MHC I molecule (19) . A final method measures the total p/MHC levels on the cell surface using antibodies specific for peptide loaded MHC molecules (20) . This provides a window on the overall efficiency of the antigen processing machinery without requiring knowledge of specific peptides or the T cells to detect them (21) (22) (23) .
With assays to measure the final p/MHC, the study of antigen processing involves experimentally manipulating the precursors and the cells in various ways and correlating changes in the p/MHC expression with the intervening steps.
ANTIGENIC PEPTIDES ARE DERIVED FROM A WIDE RANGE OF PRECURSORS
With the notable exceptions of the Epstein Barr virus-derived EBNA I protein and the cytomegalovirus (CMV)-derived 72K principal immediate-early protein, no endogenously synthesized precursor appears to be excluded from entry into the antigen processing pathway (24) (25) (26) . Rammensee et al. have compiled a comprehensive list of hundreds of self and nonself peptides known to be presented by MHC I molecules (27) . This list includes peptides derived from proteins with widely varying functions, cellular locations, and abundance. This impressive diversity is important and suggests that omissions, which would constitute a blind spot for the immune system, are rare; the antigen processing mechanism operates on most, if not all, proteins available in the cell.
The original list of peptides bound to human MHC I molecules also included many peptides of unknown origin. Using the recently completed draft of the human genome sequence, we have identified putative precursors of some of these peptides (Table 1) . Even this short list of 21 precursors contains a strikingly broad spectrum of proteins. The peptide sequences are from the list of sequences marked as "unknown origin" in Reference (27) . Potential sources were identified by searching the Genbank and Celera human genome databases. The AA position indicates where in the open reading frame the peptide sequence is located.
ARE THE PRECURSORS OLD OR NEWLY SYNTHESIZED PROTEINS?
Antigenic peptides clearly represent a wide range of gene products. The nature of the precursors, however, remains an intriguing and open question. A key issue is, when does a protein enter the antigen processing pathway? One can envision four stages in the life of an endogenous protein: The polypeptide is translated by the ribosomes, the polypeptide folds, it carries out its biological function, and it is subsequently degraded. For antigen processing, using only those proteins that are being turned over after their biological function has been completed is economical and politically correct. Why not re-use parts of a protein at the end of its useful life? Contrary to this idea, recent data indicate that the bulk of antigenic peptides come from proteins degraded immediately after synthesis. Obtaining antigenic peptides from newly synthesized proteins alleviates the theoretically difficult requirement that proteins or their fragments be retrieved from different cellular compartments such as the nucleus for entry into the antigen processing pathway. Furthermore, because proteins are sampled concomitantly with their synthesis, this provides for early detection of novel peptides derived from intracellular pathogens or mutations. If polypeptides are marked for rapid degradation because they failed to fold properly or were incorrectly translated to begin with, obtaining antigenic peptides from these precursors retains the same advantage of economy as using protein turnover.
Historically it was generally believed that antigenic peptides were derived from the turnover of mature proteins. In support of this model, mature proteins artificially introduced into the cell (28) or secreted into the cytoplasm by the intracellular bacterium Listeria monocytogenes (29) were processed into antigenic peptides. Additionally, proteins can be retrieved from several subcellular compartments for entry into the pathway, indicating that there is no obligate link between protein synthesis and peptide generation. The nonclassical MHC I molecule H2-M3 presents N-formylated peptides derived from proteins synthesized in the mitochondria (30, 31) . In two instances peptides with Asn to Asp modifications were found; this is consistent with glycosylation in the ER followed by retrieval into the cytosol for entry into the antigen processing pathway (17, 32) . Several additional cases of peptides with posttranslational modifications have been reported (16, 18) . Furthermore, as predicted, when exogenous proteins were introduced into cells, the rate of peptide generation mirrored the protein half-life. Two studies demonstrating this relationship compared peptide generation from stable and unstable proteins that were constructed taking advantage of the N-end rule: Proteins with certain N-terminal amino acids are rapidly degraded by the 26S proteasome in a ubiquitin-dependent manner (33) (34) (35) . These studies unequivocally demonstrated that proteasome-mediated turnover of mature proteins can produce antigenic peptides, but they did not address the question of whether this turnover contributes a significant supply of peptides derived from endogenously synthesized precursors.
One prediction of the model in which newly synthesized proteins are the main entrants into the antigen processing pathway is that the time course of peptide generation from an endogenous precursor will correlate with its synthesis rather than degradation of the mature protein. In the first study of an endogenous precursor, Townsend and colleagues compared peptide generation from two vaccinia constructs that encoded the influenza nucleoprotein (NP) protein and differed only by the N-terminal amino acid (36) . Using CTL lysis as a measure of p/MHC expression, they found that cells expressing the unstable NP protein were more sensitive to killing by NP/D b -specific CTL than those expressing the stable protein. However, lysis by an NP/K k -specific CTL did not correlate with the difference in stability of the same precursors. In a similar experiment, cells were infected with vaccinia encoding two forms of the influenza virus matrix protein (37) . Cells expressing the stable or unstable proteins were equally sensitive to CTL lysis. One difficulty with both studies is that CTL lysis is not a quantitative measure of peptide abundance; it is possible that in the cases in which killing was equivalent, peptide abundance may have differed, but the CTL response was maximal even at the lower peptide amount. A third study from our laboratory found no difference in the amounts of naturally processed peptides generated in cells expressing pairs of DNA constructs that differed in the N-terminus of the encoded proteins (38) . Although the precursor half-lives differed by six-to ninefold, the amounts of naturally processed peptides extracted from transfected cells were comparable. Unlike the CTL lysis assays, this experiment was quantitative; a difficulty was that peptides were detectable only after both proteins had gone through multiple halflives. Nevertheless, these studies questioned the notion that peptides are generated from mature protein turnover, and they suggested a link between protein synthesis and antigen processing.
Reits et al. took an entirely different and elegant approach to the study of antigen processing and found a striking correlation between protein synthesis and peptide supply. They monitored the availability of peptides for MHC I presentation by measuring TAP activity in living cells, using the fluorescence bleaching/recovery technique (39) . TAP moves peptides from the cytoplasm into the ER, a key stage in the journey of more than 90% of antigenic peptides. After the addition of cycloheximide, a protein-synthesis inhibitor, TAP activity rapidly ceased, within 25 min in uninfected and 40 min in influenza-infected cells, suggesting a paucity of peptides. The simplest interpretation of these results is that the majority of antigenic peptides comes from newly synthesized proteins.
Schubert et al. took another novel approach (40) . They argued that if antigenic peptides came primarily from newly synthesized proteins, then inhibiting the proteasome would cause these proteins to accumulate quickly. They treated cells with and without a proteasome inhibitor, pulse-labeled them with [
35 S]methionine, and measured the total amount of radioactivity in fractionated proteins larger than 14 kDa. Addition of the proteasome inhibitor increased the total amount of radioactivity recovered immediately after labeling, and the increase occurred preferentially in high molecular weight proteins, a fraction of which were ubiqitinated. They calculated that 30% of newly synthesized proteins were degraded within 10 min. They referred to these proteins as defective ribosomal products (DRiPs) and suggested that they represent a major source of processed peptides.
Together these studies indicate that newly synthesized proteins are a major source of precursors for antigen processing. In fact, they raise the question of whether proteins at the end of their natural lives enter the antigen processing pathway at any significant rate. Nevertheless, the links between protein synthesis and protein degradation remain to be disentangled. Notably, both of these studies relied heavily on the use of inhibitors of central cellular processes, and secondary effects of these inhibitors were not ruled out.
If antigenic peptides are in fact derived primarily from newly synthesized proteins, the question arises of which new proteins are targeted for the processing pathway. Proteins that are defective in some way would naturally be degraded rapidly. Yewdell et al. proposed that DRiPs consist of prematurely terminated polypeptides and misfolded polypeptides produced from translation of bona fide mRNAs in the proper reading frame (41) . Experiments have yet to verify the importance of misfolding and premature termination in generating antigenic peptides. C-terminally truncated polypeptides are probably not a major source of antigenic peptides because an N-terminal preference is not evident in the list of known peptides compiled by Rammensee (27) or in the new list (Table 1) .
CRYPTIC TRANSLATION AS A SOURCE OF ANTIGENIC PEPTIDES
In addition to misfolded and prematurely terminated proteins, it is increasingly clear that antigenic peptides can come from sources other than translation of the primary open reading frame. Evidence comes from several experiments in which a T cell clone was used to define its cognate p/MHC I complex (Table 2 ). In one case, a murine leukemia, the antigenic peptide was tracked to the 5 untranslated region of an mRNA transcript. In nine instances-six human cancers and three virus-infected mouse models-antigenic peptides were traced to alternative open reading frames of mRNAs encoding longer proteins. In four cases of human melanomas, antigenic peptides were tracked to introns or to the intron-exon junction.
These examples indicate that unconventional peptides can elicit cytotoxic T lymphocyte responses. We suspect that such peptides may in fact play an important role in immune surveillance. Fundamentally the immune system cares about only one attribute of a peptide: whether it is self or nonself. Whether the peptide came from a functional protein or an unconventional source is irrelevant. DNA contains a wealth of information that is not captured by translation of the primary open reading frame; translation of alternate reading frames, intronic sequences, and 5 and 3 "untranslated" regions of mRNA can make this information available. The resulting polypeptides could be particularly valuable in cases in which the 
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conventional protein had few epitopes that could squeeze through the bottlenecks in the antigen processing pathway. These bottlenecks include the ability of cellular proteases to produce the processed peptide, the ability of TAP to transport the peptide into the ER, and the ability of the peptide to bind an available MHC I molecule (42) (43) (44) . Furthermore, the precursors of these peptides, which presumably have no function in the cell, are likely to be shuttled immediately to the antigen processing pathway. They would thus be early sentinels of an infection or mutation and perfect candidates for the newly synthesized proteins that are degraded by the proteasome and transported by TAP as discussed above.
These peptides are often termed cryptic, because the mechanism of their translation is unknown. Thierry Boon and Aline Van Pel were the first to offer an explanation in the form of the pepton hypothesis (45). They argued that antigenic peptides were not degradation products of cellular proteins at all but instead were generated directly by the "autonomous transcription and translation of short subgenic regions" called "peptons" using a novel RNA polymerase. Although there is no evidence to date for this specialized transcriptional machinery, Boon & Van Pel deserve credit for directing attention toward unconventional sources of antigenic peptides. A second mechanism that could account for these peptides is mis-splicing of primary transcripts. Mis-splicing could explain translation of intronic sequences; it could also lead to transcripts missing the primary AUG codon, allowing translation to begin at an out-of-frame initiation codon. In this context a recent report of coupled transcription and translation in the nucleus is intriguing; the authors suggest that this accounts for 10-15% of protein synthesis in the cells and provides a mechanism for nonsense-mediated decay (46). The proximity of the proteasome to the nuclear translational site could make these polypeptides available to the antigen processing pathway as well.
Cryptic peptides could also be generated by the ribosome translating a conventional mRNA transcript in an unconventional way. The accepted model of translation is that the ribosome binds mRNA at the 5 cap, scans in the 3 direction for the first AUG, and translates nucleotides in triplets until a stop codon is reached. Cryptic peptides would be generated if the ribosome (a) bound the mRNA at the 5 cap but scanned through the primary AUG to start at a downstream initiation codon, (b) bound the mRNA at an internal site and initiated translation at a codon downstream of the primary AUG, or (c) initiated translation at the primary AUG and frameshifted during elongation. Bullock & Eisenlohr demonstrated that ribosomal scan-through of the primary AUG is a potent mechanism for translation of alternate reading frames (47). The pool of potential precursors was widened by studies showing that initiation of antigenic peptides can occur not only at alternate AUGs but at several additional codons (48, 49). Malarkannan also implicated a novel initiation mechanism for generation of antigenic peptides: When initiation occurred at the CUG codon (one of the non-AUG codons), it was decoded as leucine rather than the canonical methionine. The underlying molecular mechanisms that allow the translation of these polypeptides and target them into the antigen processing pathway are unknown.
Cryptic peptides could enhance immune surveillance by adding to the diversity of peptides displayed on the cell surface. However, many open questions remain; the most basic issue requiring resolution is whether cryptic translation is a rare anomaly, seen only in virally infected, transformed, or transfected cells, or whether it occurs systematically in normal cells as well. A second important question is the relative contribution of cryptic translation to the total peptide pool, in terms of numerical abundance, diversity, and immunological significance.
THE ANATOMY, DIVERSITY, AND ABUNDANCE OF NATURALLY PROCESSED PEPTIDES
Whereas our knowledge of the pool of precursors for antigen processing is still rather murky, the picture of the final product is crystal clear. The final products are short, usually 8-10 residue, peptides bound to MHC I molecules on the cell surface. A cell from a heterozygous individual expresses several hundred thousand copies of up to six different MHC I molecules. Each MHC I molecule contains a single peptide. Thus, it is possible for a single cell to express thousands of distinct p/MHC I complexes.
Most peptides displayed by a given MHC I molecule share a consensus motif defined strictly by size and the presence of conserved residues at defined positions. The consensus motifs for MHC I-bound peptides were first discovered by sequencing the mixture of peptides eluted from purified MHC I molecules (44, 50). These "simple" yet elegant experiments yielded remarkably profound insights into the mechanism that permits MHC I to bind a diverse set of peptides that is essential for effective immunesurveillance. As expected, the MHC I-bound peptide pool was heterogenous, but conserved amino acids were clearly present at one or two internal, usually the p2, p3, or p5, positions and at the C-terminus. In contrast, residues at other positions were highly variable. The variability of these six or seven residues in octamer or nonamer peptides allows up to 20 [6] [7] (∼1 × 10 8 ) different peptides to be presented by any one MHC I molecule. The crystal structures of many peptide/MHC I complexes subsequently showed that the peptides were primarily tethered to the MHC molecule by their N-and C-termini, the side chains of the conserved carboxyl and internal residues, and the peptide backbone (51).
Notable exceptions to the peptide length, consensus motifs, and mode of binding have been found among the peptides presented by MHC I molecules. In general these and other exceptions are a result of amino acid combinations in the antigenic peptide that alter the peptide conformation or can serve as secondary anchor residues to provide requisite stability to the p/MHC I complex (54). Together the variable residues of the peptide as well as the surface of the MHC molecule interact with the TCR to provide highly specific recognition of even very subtle changes in the antigenic peptides (55).
The number of peptides that can be presented by a given MHC I molecule is constrained by the consensus motifs required for binding. Even this constraint, however, is alleviated because a heterozygous individual expresses up to six different MHC I molecules; as of July 2001, almost 800 MHC I alleles had been discovered in the human population as a whole (http://www3.ebi.ac.uk/Services/imgt/hla/cgibin/statistics.cgi). The highly polymorphic nature of the MHC I loci generates amino acid substitutions within the antigen-binding groove of the MHC molecules. As a result the complementary pockets of the MHC I that accommodate the primary and secondary anchor residues of the antigenic peptide vary extensively. Accordingly, the consensus motifs are remarkably variable among the peptides bound to different MHC I molecules. This is illustrated by the presence of over 48 different consensus motifs among the 69 MHC I molecules surveyed by Rammensee and his colleagues (27) . The "X-Proline(P)-Xn" motif represents a notable exception to the high variability found among the MHC-bound peptide motifs. The "X-P-Xn" motif accounts for over 20% of all known motifs in the human and other species (27, 56) . However, the predominance of this motif is paradoxical because TAP excludes peptides with this motif from transport into the ER (43, 57). We discuss a possible explanation for this paradox later. Nevertheless, the high overall variability of consensus motifs makes it possible that any one individual can present six entirely distinct sets of peptides. This peptide diversity provides the basis for efficient immunesurveillance by CD8 + T cells but also poses special challenges for the antigen processing mechanisms responsible for generating these peptides for loading the MHC I molecules.
The diversity in the sets of peptides presented by the MHC I molecules also implies that the overall abundance of individual peptide/MHC I complexes detected by antigen-specific CD8 + T cells must be quite low. CD8 + T cells possess an impressive capacity to recognize and respond to as few as one p/MHC on the target cell surface (58). Compelling evidence directly demonstrating the complexity of the peptide pool at the level of individual peptides has been obtained using sensitive mass spectrometric analysis (59). The authors estimated that although some peptides were presented at several hundred copies/cell, others, possibly thousands, could be presented at far lower levels. Most important, the low abundance of specific p/MHC complexes displayed on the cell surface has been confirmed in experiments in which the naturally processed peptides were quantitated in antigen presenting cell (APC) extracts and were in many cases present at fewer than 10 copies/cell (60-62).
The antigen processing machinery faces an extraordinary challenge: It must produce a set of peptides that are enormously diverse and yet are precisely cleaved to conform to the consensus motifs of the MHC I molecules expressed in the cell. The remainder of this review addresses some of the key questions about how this is achieved.
THE RAMMENSEE PARADOX: MHC I MOLECULES INFLUENCE ANTIGEN PROCESSING
An absolutely critical issue in understanding the transformation of precursor polypeptides to the exactly cleaved peptides is the role of the MHC I molecules. Are MHC I molecules passive recipients of the peptides made available to them, or do they affect the antigen processing events? The important role of MHC I molecules in influencing the outcome of the antigen processing reactions was first underscored a dozen years ago by the Rammensee laboratory. Soon after the recognition that naturally processed peptides could be detected in cell extracts fractioned by high performance liquid chromatography (HPLC) (12, 13, 63), Rammensee and his colleagues compared cells expressing the antigen and the appropriate MHC I molecule with cells that expressed the antigen alone (64, 65) . Most surprisingly, they found that each of three minor histocompatibility and two influenza virus-specific CTLs could detect their cognate peptides only in extracts of cells that expressed the appropriate MHC I molecule. With rare exceptions (66), these observations of the ability to detect the final processed peptide only in the presence of the appropriate MHC I have been consistently reproducible in different model systems and laboratories (67) (68) (69) (70) (71) . How the MHC I molecules in the ER could influence the naturally processed peptide pool believed to be generated in the cytoplasm has remained an enduring paradox with profound implications for understanding the antigen processing pathway.
To explain the Rammensee paradox, one hypothesis, termed here the "protection" model, was advanced by Elliott and colleagues (72) . The protection model suggested that the processed peptides were generated in the cytoplasm but were extraordinarily labile and rapidly degraded. The processed peptides were therefore not detectable in cell extracts unless they were protected by binding to MHC I. An alternative hypothesis proposed by Falk et al. suggested that the MHC I molecules themselves were essential for generating the final version of the naturally processed peptides by acting as "templates" (64) .
Most importantly these two hypotheses had very different implications for the nature of the cytoplasmic peptide pool. The protection model implied that cytoplasmic proteolysis generated the final processed peptide, which was rapidly transported by TAP and immediately loaded onto the MHC I molecules in the ER (72) . However, the "template" model did not require that the final peptide be generated in the cytoplasm or even be labile. The cytoplasmic precursors could have additional flanking residues, but ER proteases would be essential for trimming the extra flanking residues under the influence of the MHC I molecules (64) .
Recent studies discussed below provide plausible explanations for the resolution of this paradox and insights into the intermediate steps between the precursors and their final peptide products.
MAKING THE CUTS
Regardless of the source and the sampling criteria used, all normal precursors must be fragmented to generate the precisely cleaved peptides presented by MHC I molecules. Whereas passage through the proteolytic steps is not obligatoryantigenic precursors that exactly match the final peptide product are efficiently presented by MHC I (49, 70)-all known naturally processed peptides are embedded within a polypeptide chain. This internal location dictates that precise N-and C-terminal cuts must be made to remove all flanking residues.
It is conceivable that a single endopeptidase, such as the proteasome, could cleave the antigenic precursors in a concerted manner to release the final peptide and satisfy the expectation of the protection model (73) . However, the recent discovery of proteolytic intermediates and related evidence indicate that different proteolytic mechanisms account for generating the precise C-and N-termini of the final peptide products.
Proteolytic intermediates longer than the final peptide cannot normally be detected because they are inactive in exogenous T cell assays. This was a major limitation that prevented analysis of such intermediates earlier (64, 69) . Paz et al. devised a new method that combined HPLC fractionation of cell extracts to separate the different intermediates with protease treatments to release the optimally active antigenic peptides from inactive precursors, allowing their detection by T cell activation (74, 75) . This new method for analysis of processed peptides revealed that cells do not generate the exact peptide in a single step. Instead the cells generated a number of proteolytic intermediates containing the antigenic peptide with one to four or more flanking residues. The composition of intermediates in the cytosol was distinct from that of the ER, and only the shorter set of peptides was transported by TAP. The Paz analysis provides a key insight into the Rammensee paradox. Antigen processing in the cytoplasm did not generate exactly cleaved peptides as envisaged in the protection model (72) .
Next we discuss our understanding of the proteolytic mechanisms that generate the final peptides with the exact "start," the N-terminus, and the "end," the Cterminus.
STARTING AT THE "END": GENERATING THE C-TERMINUS OF ANTIGENIC PEPTIDES
The Paz study discussed in the previous section was limited by the precursor design in which the antigenic peptide was located at the C-terminus (74) . Unlike natural precursors, generation of the intermediates that yielded the final SL8 peptide from this precursor required only N-terminal and no C-terminal cleavages. How do cells generate the precise ends, the C-termini of antigenic peptides? Several lines of evidence indicate that the C-terminal ends of antigenic peptides are generated in the cytoplasm and are made by the proteasome.
PROTEASOMES IN THE ANTIGEN PROCESSING PATHWAY
Antigen processing begins in the cytoplasm, and the proteasome plays a central role. Following the clue that two MHC linked genes, LMP2 and LMP7, were subunits of the multicatalytic proteasomes (76), the Rock and Goldberg laboratories provided the first key insight into the proteolytic mechanism for generating antigenic peptides (77) . They showed that inhibiting proteasome activity caused a profound block in the turnover of short-and long-lived intracellular proteins and also abrogated the generation of p/MHC I complexes in cells. Numerous subsequent studies have confirmed that the proteasome is the key protease in the generation of p/MHC I complexes (78) . For most antigenic peptides, specifically inhibiting the proteasome causes loss of presentation, but for reasons not yet clear the presentation of some peptides actually increases in cells treated with proteasome inhibitors (21, 79, 80) .
Recognizing the importance of the proteasomes in generating the processed peptides, many studies have focused on defining its structure and role in antigen processing. These studies have been recently reviewed (78, 81, 82) . The proteasome is a complex and heterogenous structure with several distinct catalytic activities. In addition to the constitutive 20S proteasome expressed in most cells, the "immunoproteasome" is the predominant species in lymphoid tissues. The latter includes the γ -interferon-inducible subunits LMP2, LMP7, and MECL-1 that replace the constitutive subunits (83) . These 20S core particles can be further modified by the addition of a 19S cap structure as well as by the γ -interferon-inducible PA28α and PA28β.
The proteasome, owing to its central role in many distinct biological processes such as signal transduction pathways and the cell cycle, is essential for cell viability. Notwithstanding reports that other proteases can replace proteasome function (84, 85) , knock-outs of the delta or X subunit of the constitutive proteasome (replaced by LMP2 and LMP7, respectively, in the immunoproteasome) are lethal at the very early pre-implantation state of development (J. Monaco, personal communication). However, the immunoproteasome is not essential for viability, and its absence caused by knock-out of LMP2 (86), LMP7 (87) , and the MECL-1 genes (J. Monaco, personal communication) correlates with subtle defects in antigen presentation. Likewise PA28 knockout mice are impaired in their ability to process some endogenous and exogenous antigens and to generate CTL responses (88) . Note that the loss of TAP1 (89) or tapasin (90, 91) causes severe five-to tenfold reduction in the overall presentation of antigenic peptides by MHC I molecules.
In contrast, the loss of LMP2, LMP7, MECL-1, or PA28 causes far less severe defects. It is therefore very likely that the constitutive proteasome and/or other proteases are sufficient for generating most antigenic peptides for MHC I molecules, and the immunoproteasome and other modifiers influence the quality or quantity of the processed peptide pool under some circumstances.
Delineating the role of the proteasome subunits and modifications in antigen processing is an active area of research. In vitro assays using colorimetric and peptide substrates have consistently identified three major cleavage specificities of the proteasome (83) . These specificities promote cleavage after hydrophobic, basic, and negatively charged amino acids. Notably, introduction of the IFN γ -inducible subunits enhances cleavages after the basic and hydrophobic residues, consistent with peptide C-terminal preferences MHC I.
PROTEASOMES MAKE THE C-TERMINAL CUT
Several lines of evidence indicate that the proteasome is required to generate the C but not the N terminus of the final peptide. Craiu et al. used proteasome inhibitors to block presentation of the ovalbumin-derived SL8/K b complex in cells expressing precursors that were extended at the N-or C-termini (92) . They noticed that the inhibitors could block presentation of the SL8 peptide when it contained even one C-terminal flanking residue but not with up to 25 N-terminal flanking residues. Similar observations with two other antigenic peptides (93) suggested that proteasomal activity was essential only for generating the precise C-terminus and was not required for generating the precise N-terminus. Independently another study used the HPLC/enzymatic method to detect the SL8 peptide as well as the Cterminal extended SL8-I peptide in cells expressing K b and a precursor with SL8-I at its C-terminus (75) . Again in this study, the generation of naturally processed SL8 but not the SL8-I peptide required active proteasomes.
A third study examined the generation of the SL8 peptide analogs by the constitutive and immunoproteasome in vitro (94) . In a significant advance over other similar studies, the authors were able to use whole ovalbumin rather than synthetic peptides as a substrate. They found that proteasomes, particularly the immunoproteasome, preferentially generated N-terminally rather than C-terminally extended analogs of the SL8 peptide. This study supports the in vivo studies discussed above and directly implicates the proteasomes in generating the C-termini of antigenic peptides.
It is important to note that biochemical proof that the C-termini of antigenic peptides are generated in the cytosol based upon analysis of proteolytic intermediates in the cytosol is not yet available. Furthermore, the requirement that the C terminus be made in the cytoplasm does not appear to be absolute. This is illustrated by the discovery of MHC I-bound peptides that were derived from signal sequences (14, 95) and by the presentation of three different peptides from the HIV env protein in TAP deficient T2 cells (96, 97) . The location of these peptides requires liberation of both N-and C-terminal flanking residues, indicating that both N-and C-terminal trimming could occur in the secretory pathway.
OTHER CYTOPLASMIC PROTEASES
Cytoplasmic proteases other than proteasomes may also be involved in generating peptides for MHC I molecules. This evidence comes from mass-spectrometric analysis of peptide generation in proteasome-inhibited cells and from a number of T cell epitopes whose expression increases in the absence of the proteasome (21, 79, 80) . Based upon its ability to cleave peptides in vitro and its upregulation in cells surviving partial proteasome inhibition, tripeptidylpeptidase II (TPPII) was suggested to be a peptide supplier (85) . In addition, several proteases with aminopeptidase activity have been proposed to take part in the antigen processing pathway. Leucine aminopeptidase was found to generate actual antigenic peptides when potential N-terminally extended precusors were treated in vitro (98) . Notably, the expression of leucine aminopeptidase is upregulated in γ -interferon treated cells. Recently two other aminopeptidases were identified by purification from the cytosol (99) . Each of these proteases, puromycin sensitive aminopeptidase and bleomycin hydrolase, was able to trim the N-termini of synthetic peptide substrates. However, the role of these proteases in the antigen processing pathway has not yet been established and will require protease-deficient cells or highly specific inhibitors.
ARGUMENTS FAVORING THE GENERATION OF C-TERMINI IN THE CYTOSPLASM
Regardless of the mechanism, it appears that the C-terminus of the antigenic peptide must be made in the cytoplasm because proteases in the ER do not seem to be capable of C-terminal trimming. This was evident in an early study by Eisenlohr et al., who found that an antigenic precursor with two extra C-terminal flanking residues could not be presented by MHC I unless the cells also co-expressed a carboxypeptidase in the ER (100). Subsequent analyses with several different antigenic peptides have shown that N-terminal but not C-terminal extensions can be efficiently trimmed from ER-targeted antigenic precursors (101) (102) (103) . Independently the lack of carboxypeptidase activity in the ER was also inferred from the analysis of the rat cim effect (104) . The rat RT1.A a MHC molecule prefers the arginine residue at the peptide's C-terminus. RT1.A a could not be loaded with such peptides in cells that expressed the TAP2B allele because it transports peptides with hydrophobic C-termini, and these could not be trimmed back to arginine in the ER. Finally, direct quantitative analysis of naturally processed peptides showed that the ER is about 300-fold less efficient in trimming C-rather than N-terminal flanking residues from an antigenic peptide (23) . Together these studies strongly support the idea that C-termini are made in the cytoplasm because they are inefficiently generated in the ER.
The second attractive feature of generating the C-termini of antigenic peptides in the cytoplasm is that it could explain the intriguing link between TAP specificity and the conserved C-termini of MHC binding motifs. In the mouse and rat cim b strain, for example, TAP prefers to transport peptides with hydrophobic C-termini, mirroring the C-terminal preference of the available MHC I molecules. Whereas the C-terminal bias of TAP is consistent with MHC I-binding motifs, the length preference of TAP is variable. Peptides significantly longer than binding motifs allowed are efficiently transported, suggesting that further trimming, possibly at the N-terminus, might be required in the ER (105, 106) . Analysis of TAP transport specificity in vivo is also consistent with this analysis (107) . Therefore, a general correspondence between the C-terminus specificity of the proteasome TAP and MHC binding underscores the importance of cytoplasmic events in generating the C-termini of peptides presented by MHC I.
SHUTTLING THE INTERMEDIATES
How the cytoplasmic intermediates en route to TAP get there is not known. Peptides may simply diffuse or may be specifically shuttled assisted by chaperones. Several independent studies have shown that cytosolic and ER heat shock proteins hsp70, hsc73, hsp90, and gp96 are associated with antigenic peptides and can elicit donor APC-specific CTL responses (reviewed in 108). These studies have unequivocally shown that these chaperones are associated with antigenic peptides, but the functional role of these chaperones in the antigen processing pathway is not clear. Recently Binder et al. showed that cells presented specific p/MHC I with a high efficiency when peptide-loaded hsp70 or hsp90 were introduced into the cytoplasm (109) . Furthermore, cells treated with deoxyspergualin, which binds these heat-shock proteins, disrupted antigen presentation. Similar findings were also reported by T. Torigoe and N. Sato (personal communication). In addition they determined that hsc73 can physically associate with TAP, providing a potential role for peptide-loaded heat-shock proteins in peptide delivery to TAP. This may increase the p/MHC I presentation efficiency by decreasing nonspecific degradation in the cytosol. Because peptide association with the chaperones can serve as an important check-point in the antigen processing pathway and influence the overall efficiency of p/MHC I expression, this is an important area of research and is reviewed by Srivastava in this volume.
THE "START" AT THE END: AMINOPEPTIDASES GENERATE THE N-TERMINUS IN THE ER
There is now good evidence indicating that for most peptides, the C-terminus is generated in the cytoplasm. The N-terminal trimming necessary to generate the start of the antigenic peptide appears to be less constrained and may occur in either the cytoplasm or the ER. Several recent studies have established the general importance of ER aminopeptidases for the generation of many antigenic peptides.
Whereas we refer to these events as occurring in the ER, we emphasize that this location has not been firmly established. The studies most pertinent to this issue have been carried out either in isolated microsomes (as representative of the ER) or in cells lacking TAP, in which antigenic precursors are introduced into the ER via the translocon. It is conceivable that microsomes may be contaminated with other organelles and that antigenic precursors introduced into the ER may have been processed in post-ER compartments and returned into the ER by retrograde transport (110, 111) . Therefore, strictly speaking the site of processing in these studies is actually a post-TAP compartment that we refer to here as the ER because MHC I are located and loaded in this compartment, as well as for the sake of brevity.
As reviewed above, studies using ER-targeted precursors have shown that Nterminal but not C-terminal flanking residues can be efficiently cleaved from antigenic peptides in the ER. However, because the precursors used in these studies were targeted into the ER necessarily bypassing TAP, it was unclear whether these precursors were trimmed by proteases that were an integral part of the normal antigen processing pathway.
Three recent studies have addressed this issue. Paz et al. performed a direct biochemical analysis of the intermediates to the SL8 peptide using their novel HPLC/enzymatic method. They found that N-terminally extended intermediates, and not the minimal peptide, were transported into the ER in living cells. In the presence of K b , these precursors were trimmed and high levels of the K b /SL8 complex were generated (74) . In a second study, Lavau et al. showed that two antigenic peptides presented by HLA-A2 were poor substrates for TAP in vitro, and when expressed as minimal precursors in the cytoplasm they were not presented (112) . Interestingly, extending these precursors to include either one or two N-terminal amino acids greatly enhanced the ability of these peptides to be transported by TAP, and similar extensions of the minimal precursors enabled in vivo presentation. Finally, Serwold et al. treated cells with the aminopeptidase inhibitor leucinethiol, which blocked peptide trimming in the ER, and they found a 30-70% reduction of surface MHC I expression, clearly showing that aminopeptidase trimming in the ER is an essential component of the antigen processing pathway (23).
Serwold et al. also systematically defined the specificity of the ER aminopeptidase using a series of ER targeted precursors with N-terminal extensions (23) . All N-terminal amino acids, with the important exception of proline, could be efficiently trimmed from the precursors. Instead of being trimmed to the minimal peptide, proline-flanked precursors were trimmed to yield products with the "X-Pro" sequence at their N-terminus (X-P-Xn). Interestingly, the expression of L d , which prefers X-P-Xn peptides, was severely reduced in cells treated with leucinethiol. This is consistent with the idea that the generation of the X-P-Xn requires aminopeptidase activity and that these peptides are used by MHC I.
Aminopeptidase trimming of precursors in the ER to preferentially generate X-P-Xn peptides provided a plausible solution to another paradox in the antigen processing pathway. TAP translocation assays have consistently shown that peptides containing proline in position 2 are the least preferred substrates for TAP (43, 57) . Therefore, it was rather surprising that this "untransportable" sequence should account for approximately 20% of known MHC I-binding motifs (27, 56 ). Serwold's observation that aminopeptidase trimming leads to the preferential accumulation of X-P-Xn peptides explained the source of these peptides and also suggested that MHC I molecules that bind to the X-P-Xn motif may have evolved to take advantage of this abundant pool of peptides. An interesting corollary is the possibility that TAP evolved to avoid transporting X-P-Xn peptides specifically because these could not be further tailored. Interestingly, the "X-P" sequence is found not only among peptides loaded onto MHC I, but also among a number of other ER resident proteins in the antigen processing pathway. Tapasin, calreticulin, and β2M, as well as some MHC I alleles share the same X-P residues at their N-termini, suggesting that they too might need protection from a highly active aminopeptidase in the vicinity of the peptide loading complex.
Together these studies provide compelling arguments for aminopeptidase trimming in the ER as a key event in the antigen processing pathway. However, the molecular mechanism of ER trimming is obscure. An interesting candidate was recently suggested by the Srivastava group, who discovered that gp96, an ERresident chaperone, possesses aminopeptidase activity (113) . This is an intriguing observation because gp96 is well known for its ability to bind antigenic peptides (108) . The authors note, however, that the gp96 aminopeptidase activity is extremely weak, a million-fold lower than that of the benchmark aminopeptidase M. Whether low enzymatic activity rules out gp96 as the putative ER aminopeptidase or whether its high abundance compensates for its low activity remains to be determined.
MHC MOLECULES AS TEMPLATES FOR N-TERMINAL TRIMMING IN THE ER
The notion that the N-terminal flanking residues of many peptides are trimmed in the ER raises the question of how this trimming is accomplished. In the context of the Rammensee paradox, the MHC I molecules could define the peptide pool in the ER by two different mechanisms (64) . The proteolytic intermediates could be processively trimmed at the N-terminus independently of the MHC I. The product of each cleavage cycle could be tested for binding to the MHC I molecules so that once the optimal peptide is made it could be firmly bound and remain protected from further trimming. Alternatively, the extended intermediates could associate with the peptide receptive MHC I molecules, which could then serve as a template for the aminopeptidase until the optimal N-terminus was achieved.
Whereas the influence of MHC I on the peptide pool is clear, distinguishing these two models has remained difficult. In one study a nonapeptide (M-SL8) and an octapeptide (SL8) were shown to bind K b on the cell surface (69) . In addition, when M-SL8 was expressed as a precursor in cells, it was presented by D b , showing that it was present in the ER. Nevertheless, only SL8, but not M-SL8, was recovered from K b expressing cells, suggesting the possibility that the M-SL8 nonapeptide was first bound to K b in the ER and was then trimmed to the SL8 peptide. Alternatively, it was possible that a quality control mechanism prevented M-SL8/K b binding in the ER but not on the cell surface. Stronger evidence favoring a role of MHC I molecules in trimming peptides was noted by Paz et al. (74) . In cells without K b Paz et al. found an N-terminally extended K-SL8 peptide in ER extracts. Remarkably, in cells expressing K b this precursor decreased dramatically with a concomitant increase in the accumulation of the K b -bound SL8 peptide. The simplest interpretation of this result is that the N-terminally extended K-SL8 peptide was a precursor for SL8 and that its conversion required the K b MHC molecule. A prediction of the template model of antigen processing is that MHC I molecules should be bound to extended peptides before the final peptide product is generated. Brouwenstijn in our laboratory recently discovered such complexes in isolated murine microsomes pulsed with N-terminally extended precursors (114) . These extended peptide/MHC I complexes were rapidly converted to the optimal peptide/MHC I complexes by an aminopeptidase activity. The discovery of this intermediate together with the Paz and Serwold studies discussed above provide a satisfactory resolution to the Rammensee paradox. They explain why the naturally processed peptides are not found in cells expressing the antigen without the MHC I. The antigen processing mechanism provides only N-terminally extended peptides to the ER that cannot be normally detected owing to the sensitivity limits of the methods. Whether similar extended peptide-bound MHC I complexes exist in vivo is not known. Also, the mechanism of template-driven trimming of extended peptides and the identity of the aminopeptidase have not yet been defined.
A GENERAL MODEL FOR THE P/MHC I ANTIGEN PROCESSING PATHWAY
In conclusion, based upon the evidence discussed above, we suggest a model for the MHC I antigen processing pathway. Newly synthesized polypeptides including cryptic translation products serve as the primary source of antigenic peptides. The precursors are cleaved by the proteasome and other proteases to generate a mixture of proteolytic intermediates that have the correct C-terminal end of the antigenic peptide. The intermediates, perhaps assisted by cytoplasmic chaperones, are transported by TAP into the ER. After transport into the ER, the extra Nterminal residues are processively removed by an aminopeptidase, likely using the MHC as a template, until the product fits the antigen-binding groove of the MHC I molecule with high affinity. This final peptide/MHC I complex exits the ER and serves as a potential ligand for CD8 + T cells on the APC surface.
Several features of this model make it attractive for explaining the efficiency of the antigen processing pathway. First, using newly synthesized precursors rather than protein turnover as the primary source of antigenic peptides allows the antigen processing mechanism to tap into the total range of polypeptides synthesized in the cells, regardless of when and where the mature proteins are degraded. This mechanism would also accelerate the recognition of abnormal cells. Second, the stepwise proteolysis of precursors has important implications for the efficiency of peptide generation. Cytoplasmic processing in this view yields a rough-draft of the final peptide with the correct C-terminus. Cytoplasmic processing and transport, by making the C-termini, essentially define which peptides can be presented. Nonetheless, the proteolytic mechanisms do not bear the burden of generating the exact peptides that the MHC I molecules need in the ER. ER trimming of N-terminal flanking residues, under the guidance of MHC I molecules, enables the mechanism to be flexible, and at the same time, maximizes precision.
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